Cargando…

Diagnostic laboratory testing for Charcot Marie Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies

BACKGROUND: Current genetic test algorithms for Charcot Marie Tooth (CMT) disease are based on family details and comprehensive clinical and neurophysiological data gathered under ideal conditions for clinical assessment. However, in a diagnostic laboratory setting relying on external test requisiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Østern, Rune, Fagerheim, Toril, Hjellnes, Helene, Nygård, Bjørn, Mellgren, Svein I, Nilssen, Øivind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849068/
https://www.ncbi.nlm.nih.gov/pubmed/24053775
http://dx.doi.org/10.1186/1471-2350-14-94
_version_ 1782293871691038720
author Østern, Rune
Fagerheim, Toril
Hjellnes, Helene
Nygård, Bjørn
Mellgren, Svein I
Nilssen, Øivind
author_facet Østern, Rune
Fagerheim, Toril
Hjellnes, Helene
Nygård, Bjørn
Mellgren, Svein I
Nilssen, Øivind
author_sort Østern, Rune
collection PubMed
description BACKGROUND: Current genetic test algorithms for Charcot Marie Tooth (CMT) disease are based on family details and comprehensive clinical and neurophysiological data gathered under ideal conditions for clinical assessment. However, in a diagnostic laboratory setting relying on external test requisitions and patient samples, such conditions are not always met. Our objective was therefore to perform a retrospective evaluation of the data given in laboratory request forms and to assess their quality and applicability with regard to the recommended algorithms for CMT diagnostics. As we are the main test centre for CMT in Norway our results also provide an overview of the spectrum of gene defects in the Norwegian CMT population. METHODS: Genetic testing was performed according to polyneuropathy type; demyelinating/mixed: PMP22 duplication, MPZ, EGR2, LITAF, NEFL, PMP22, GJB1, axonal: MFN2, MPZ, NEFL, and GJB1. RESULTS: Diagnostic testing of index patients was requested in 435 of the 549 cases. Seventy-two (16.6%) positive molecular genetic findings were made. The majority (94.6%) of mutation positive cases showed disease onset before 50 years of age. PMP22 (duplication), MPZ, GJB1 and MFN2 mutations constituted 95.8% of the positive findings. Within the nerve conduction study groups, mutation detection rates were; demyelinating 33.8%; mixed 29.0%; axonal 8.8%; unspecified 16.5%. CONCLUSION: We suggest a simplified algorithm intended for referral centres, dealing with DNA/blood samples, which involves the assessment of age at onset and neurophysiological data followed by testing of four genes; PMP22 (duplication), MPZ, GJB1 and MFN2. Patients negative for mutations in those four genes should be subjected to evaluation at an interdisciplinary inherited neuropathy clinic with the capacity for extended molecular genetic analysis by next generation sequencing.
format Online
Article
Text
id pubmed-3849068
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38490682013-12-04 Diagnostic laboratory testing for Charcot Marie Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies Østern, Rune Fagerheim, Toril Hjellnes, Helene Nygård, Bjørn Mellgren, Svein I Nilssen, Øivind BMC Med Genet Research Article BACKGROUND: Current genetic test algorithms for Charcot Marie Tooth (CMT) disease are based on family details and comprehensive clinical and neurophysiological data gathered under ideal conditions for clinical assessment. However, in a diagnostic laboratory setting relying on external test requisitions and patient samples, such conditions are not always met. Our objective was therefore to perform a retrospective evaluation of the data given in laboratory request forms and to assess their quality and applicability with regard to the recommended algorithms for CMT diagnostics. As we are the main test centre for CMT in Norway our results also provide an overview of the spectrum of gene defects in the Norwegian CMT population. METHODS: Genetic testing was performed according to polyneuropathy type; demyelinating/mixed: PMP22 duplication, MPZ, EGR2, LITAF, NEFL, PMP22, GJB1, axonal: MFN2, MPZ, NEFL, and GJB1. RESULTS: Diagnostic testing of index patients was requested in 435 of the 549 cases. Seventy-two (16.6%) positive molecular genetic findings were made. The majority (94.6%) of mutation positive cases showed disease onset before 50 years of age. PMP22 (duplication), MPZ, GJB1 and MFN2 mutations constituted 95.8% of the positive findings. Within the nerve conduction study groups, mutation detection rates were; demyelinating 33.8%; mixed 29.0%; axonal 8.8%; unspecified 16.5%. CONCLUSION: We suggest a simplified algorithm intended for referral centres, dealing with DNA/blood samples, which involves the assessment of age at onset and neurophysiological data followed by testing of four genes; PMP22 (duplication), MPZ, GJB1 and MFN2. Patients negative for mutations in those four genes should be subjected to evaluation at an interdisciplinary inherited neuropathy clinic with the capacity for extended molecular genetic analysis by next generation sequencing. BioMed Central 2013-09-21 /pmc/articles/PMC3849068/ /pubmed/24053775 http://dx.doi.org/10.1186/1471-2350-14-94 Text en Copyright © 2013 Østern et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Østern, Rune
Fagerheim, Toril
Hjellnes, Helene
Nygård, Bjørn
Mellgren, Svein I
Nilssen, Øivind
Diagnostic laboratory testing for Charcot Marie Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies
title Diagnostic laboratory testing for Charcot Marie Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies
title_full Diagnostic laboratory testing for Charcot Marie Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies
title_fullStr Diagnostic laboratory testing for Charcot Marie Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies
title_full_unstemmed Diagnostic laboratory testing for Charcot Marie Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies
title_short Diagnostic laboratory testing for Charcot Marie Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies
title_sort diagnostic laboratory testing for charcot marie tooth disease (cmt): the spectrum of gene defects in norwegian patients with cmt and its implications for future genetic test strategies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849068/
https://www.ncbi.nlm.nih.gov/pubmed/24053775
http://dx.doi.org/10.1186/1471-2350-14-94
work_keys_str_mv AT østernrune diagnosticlaboratorytestingforcharcotmarietoothdiseasecmtthespectrumofgenedefectsinnorwegianpatientswithcmtanditsimplicationsforfuturegeneticteststrategies
AT fagerheimtoril diagnosticlaboratorytestingforcharcotmarietoothdiseasecmtthespectrumofgenedefectsinnorwegianpatientswithcmtanditsimplicationsforfuturegeneticteststrategies
AT hjellneshelene diagnosticlaboratorytestingforcharcotmarietoothdiseasecmtthespectrumofgenedefectsinnorwegianpatientswithcmtanditsimplicationsforfuturegeneticteststrategies
AT nygardbjørn diagnosticlaboratorytestingforcharcotmarietoothdiseasecmtthespectrumofgenedefectsinnorwegianpatientswithcmtanditsimplicationsforfuturegeneticteststrategies
AT mellgrensveini diagnosticlaboratorytestingforcharcotmarietoothdiseasecmtthespectrumofgenedefectsinnorwegianpatientswithcmtanditsimplicationsforfuturegeneticteststrategies
AT nilssenøivind diagnosticlaboratorytestingforcharcotmarietoothdiseasecmtthespectrumofgenedefectsinnorwegianpatientswithcmtanditsimplicationsforfuturegeneticteststrategies